Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway.

Støer, Nathalie C; Bouche, Gauthier; Pantziarka, Pan; Sloan, Erica K; Andreassen, Bettina K; Botteri, Edoardo

Støer, Nathalie C; Bouche, Gauthier; Pantziarka, Pan; Sloan, Erica K; Andreassen, Bettina K; Botteri, Edoardo.

Afiliação

Støer NC; Department of Research, Cancer Registry of Norway, Oslo, Norway.
Bouche G; Anticancer Fund, Brussels, Belgium.
Pantziarka P; Anticancer Fund, Brussels, Belgium.
Sloan EK; Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Andreassen BK; Division of Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Botteri E; Department of Research, Cancer Registry of Norway, Oslo, Norway.

Acta Oncol ; 60(9): 1146-1153, 2021 Sep.

Article em En | MEDLINE | ID: mdl-34338111

Assuntos

Adenocarcinoma; Inibidores de Hidroximetilglutaril-CoA Redutases; Metformina; Neoplasias Pancreáticas; Adenocarcinoma/tratamento farmacológico; Estudos de Coortes; Humanos; Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico; Metformina/uso terapêutico; Neoplasias Pancreáticas/tratamento farmacológico; Sistema de Registros

Palavras-chave

Pancreatic cancer; beta-blocker; metformin; statin; survival

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Inibidores de Hidroximetilglutaril-CoA Redutases / Metformina Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google